AG2R LA Mondiale Gestion D Actifs Purchases 924 Shares of Becton, Dickinson and Company $BDX

AG2R LA Mondiale Gestion D Actifs grew its position in Becton, Dickinson and Company (NYSE:BDX) by 8.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,105 shares of the medical instruments supplier’s stock after acquiring an additional 924 shares during the quarter. AG2R LA Mondiale Gestion D Actifs’ holdings in Becton, Dickinson and Company were worth $2,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Saudi Central Bank bought a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $27,000. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Kelly Lawrence W & Associates Inc. CA bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $31,000. Finally, WPG Advisers LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $36,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 1,838 shares of company stock valued at $348,392. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BDX. Piper Sandler reissued a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Friday. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Finally, Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $185.85 on Friday. The stock’s fifty day moving average is $189.93 and its two-hundred day moving average is $183.97. The company has a market capitalization of $53.27 billion, a PE ratio of 33.43, a price-to-earnings-growth ratio of 1.45 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion during the quarter. As a group, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.